Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$6.8B
P/E ratio
22×
Div yield
—
EPS (TTM)
$4.80
Profit margin
20%
Rev. growth
+18%
Revenue
$1.53B
Free cash flow
$0.3B
In plain English
Lantheus is the leading US radiopharmaceutical company — it makes the short-lived radioactive tracers that light disease up on a scan. Its blockbuster PYLARIFY (an F-18 PSMA agent) made PSMA-PET the standard of care in prostate-cancer imaging and passed $1B in sales, while DEFINITY dominates ultrasound echocardiography. In Aug 2026 Curium agreed to take Lantheus private for up to ~$8B.
In simple terms
What Lantheus Holdings really sells
Lantheus is the leading US radiopharmaceutical company — it makes the short-lived radioactive tracers that light disease up on a scan. Its blockbuster PYLARIFY (an F-18 PSMA agent) made PSMA-PET the standard of care in prostate-cancer imaging and passed $1B in sales, while DEFINITY dominates ultrasound echocardiography. In Aug 2026 Curium agreed to take Lantheus private for up to ~$8B.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.